Companhia Brasileira de Distribuicao (NYSE: CBD) and Diplomat Pharmacy (NYSE:DPLO) are both retail/wholesale companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Insider and Institutional Ownership

3.5% of Companhia Brasileira de Distribuicao shares are held by institutional investors. Comparatively, 69.9% of Diplomat Pharmacy shares are held by institutional investors. 0.0% of Companhia Brasileira de Distribuicao shares are held by company insiders. Comparatively, 30.2% of Diplomat Pharmacy shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Companhia Brasileira de Distribuicao and Diplomat Pharmacy’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Companhia Brasileira de Distribuicao 0.27% 5.46% 1.65%
Diplomat Pharmacy 0.27% 7.97% 4.47%

Valuation & Earnings

This table compares Companhia Brasileira de Distribuicao and Diplomat Pharmacy’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Companhia Brasileira de Distribuicao $13.52 billion 0.49 $772.66 million $0.14 179.14
Diplomat Pharmacy $4.53 billion 0.32 $70.47 million $0.17 126.59

Companhia Brasileira de Distribuicao has higher revenue and earnings than Diplomat Pharmacy. Diplomat Pharmacy is trading at a lower price-to-earnings ratio than Companhia Brasileira de Distribuicao, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Companhia Brasileira de Distribuicao has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Diplomat Pharmacy has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Companhia Brasileira de Distribuicao and Diplomat Pharmacy, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Companhia Brasileira de Distribuicao 0 3 1 0 2.25
Diplomat Pharmacy 1 8 3 0 2.17

Diplomat Pharmacy has a consensus target price of $19.16, suggesting a potential downside of 10.98%. Given Diplomat Pharmacy’s higher probable upside, analysts plainly believe Diplomat Pharmacy is more favorable than Companhia Brasileira de Distribuicao.

Summary

Diplomat Pharmacy beats Companhia Brasileira de Distribuicao on 7 of the 13 factors compared between the two stocks.

Companhia Brasileira de Distribuicao Company Profile

Companhia Brasileira de Distribuicao, directly or through its subsidiaries, is engaged in the retail of food, clothing, home appliances, electronics and other items through its chain of hypermarkets, supermarkets, specialized stores and department stores principally under the trade names Pao de Acucar, Minuto Pao de Acucar, Extra Hiper, Extra Super, Minimercado Extra, Assai an the neighborhood shopping mall brand Conviva. The Company’s segments include Retail, and Cash and carry segment. The Company’s Retail segment includes the banners Pao de Acucar, Minuto Pao de Acucar, Extra Hiper, Extra Supermercado, Minimercado Extra, Posto Extra, Drogaria Extra and GPA Malls & Properties. Its Cash & Carry segment includes the brand Assai. The Company is engaged in operations of retail stores located in approximately 20 states and the Federal District of Brazil.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s patient care system is used to coordinate and track patient adherence and safety.

Receive News & Ratings for Companhia Brasileira de Distribuicao Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Companhia Brasileira de Distribuicao and related companies with MarketBeat.com's FREE daily email newsletter.